compound introduction
BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with K i values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects In Vivo BPR1M97 (1.8 mg/kg; s.c.; once) demonstrates antinociception in a murine model of cancer pain . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male wild-type C57BL/6 mice (25-30 g) Dosage: 1.8 mg/kg Administration: Subcutaneous injection (s.c.); once Result: Demonstrated antinociception in a murine model of cancer pain. IC50& Target:Ki: 1.8 nM (MOP), 4.2 nM (NOP)
